フロリダ州における脳腫瘍の臨床試験
フロリダ州内の拠点で、脳腫瘍に関する29件の研究が参加者を募集しています。
フロリダ州内の都市
公式研究テキスト（英語）
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
- Mayo Clinic in Florida, Jacksonville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05222620Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Miami Cancer Institute, Miami
- Moffitt Cancer Center, Tampa
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07326566Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- MDR Core Network, Boynton Beach
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
- UF Health, Gainesville
被験者募集中第1相
18歳〜80歳 · 全性別 · 2026/09/23更新 · NCT06389591A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Orlando Health Cancer Institute, Orlando
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04511013Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Orlando Health Arnold Palmer Hospital for Children, Orlando
- St. Joseph's Children's Hospital, Tampa
被験者募集中第2相
59 Months · 全性別 · 2026/09/15更新 · NCT05535166A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Miami, Miami
- Comprehensive Hematology Oncology, St. Petersburg
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Mayo Clinic_Jacksonville, Jacksonville
- Baptist Health Miami Cancer Institute, Miami
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07428616Targeted Pediatric High-Grade Glioma Therapy
- University of Miami, Miami
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- University of Miami Hospital and Clinics, Miami
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
- Broward Health, Fort Lauderdale
- Miami Cancer Institute at Baptist Health, Miami
- Moffitt Cancer Center, Tampa
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/08/19更新 · NCT05317858Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
- Mayo Clinic in Florida, Jacksonville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT03750227Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
- Baptist Health Herbert Wertheim Cancer Institute, Miami
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT06991101Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
- University of Miami, Miami
被験者募集中
18歳以上 · 全性別 · 2026/07/29更新 · NCT05284643Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- BayCare Health, Clearwater
- Ascension St. Vincent's, Jacksonville
- Miami Cancer Institute, Baptist Health South Florida, Miami
- 他4件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/22更新 · NCT04427384A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
- UF Health, Gainesville
被験者募集中第1相
4歳以上 · 全性別 · 2026/06/25更新 · NCT04573140Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/09更新 · NCT03550391Intravital Microscopy in Human Solid Tumors
- Mayo Clinic Florida, Jacksonville
被験者募集中
18歳以上 · 全性別 · 2026/06/02更新 · NCT03823144ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
- University of Florida Health Shands Hospital, Gainesville
被験者募集中第1相
18歳〜89歳 · 全性別 · 2026/05/27更新 · NCT0625432618F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
- Miami Cancer Institute, Miami
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/20更新 · NCT06048094Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
- Miami Cancer Institute, Miami
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/22更新 · NCT04689048Non-invasive Glioma Characterization Through Molecular Imaging
- University of Miami, Miami
被験者募集中
18歳以上 · 全性別 · 2026/04/20更新 · NCT03684109Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Mayo Clinic Jacksonville, Jacksonville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544Cancer Genetic Testing in Ethnic Populations
- Mayo Clinic in Florida, Jacksonville
被験者募集中
18歳以上 · 全性別 · 2026/04/02更新 · NCT04475640cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Miami Cancer Institute, Miami
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881Florida Center for Brain Tumor Research
- University of Florida, Gainesville
被験者募集中観察研究
全年齢 · 全性別 · 2026/01/13更新 · NCT00811148Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
- Miami Cancer Institute at Baptist Health South Florida, Miami
被験者募集中第2相
18歳以上 · 全性別 · 2025/12/01更新 · NCT05554302S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Moffitt Cancer Center, Tampa
- Cleveland Clinic-Weston, Weston
被験者募集中第3相
18歳以上 · 全性別 · 2025/10/08更新 · NCT03418961A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- Florida Cancer Center, Lake Mary
被験者募集中第1/2相
18歳〜89歳 · 全性別 · 2025/08/19更新 · NCT06907043ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。